槐耳颗粒联合吉非替尼治疗晚期肺腺癌的研究

探讨槐耳颗粒联合吉非替尼在晚期肺腺癌治疗中的临床应用价值。将患者随机分为治疗组和对照组，治疗组采用口服槐耳颗粒联合吉非替尼，对照组单纯口服吉非替尼。4个疗程后，分别观察两组治疗前后机体免疫状态、瘤体大小、生存质量的变化和药物毒副反应等指标。结果发现两组患者瘤体大小和生存质量差异无统计学意义（P＞0．05），但治疗组和对照组比较 CD8＋明显下降、CD4＋／CD8＋比值上升，差异有统计学意义（P＜0．05），毒副反应方面，恶心呕吐、腹泻等药物不良反应相对较轻，但差异无统计学意义（P＞0．05）。因此，槐耳颗粒可显著提高患者的免疫功能，有较大的临床应用价值，可以与吉非替尼联合治疗晚期肺腺癌患者。

On Huaier Particles Combined Gefitinib in Advanced Lung Adenocarcinoma

To investigate the clinical value of Huaier particles combined Gefitinib in advanced lung adenocarcinoma ,50 patients were divided randomly into two groups ,the treatment group （25 cases） and the control group （25 cases） .Huaier particles combined Gefitinib were given in the treatment group ,and Gefitinib was simply given in the control group .The changes of patients＆#39;immune status ,tumor size ,quality of life and drug toxicity followed in four courses ,were compared pre - treatment and post - treatment respectively in two groups .The results showed that tumor size and survival quality of the treatment group and the control group after treatment had no significant difference （P＆gt; 0 .05） .But after treatment , CD8 ＋ in the treatment group was significantly decreased while the ratio of CD 4 ＋ /CD8 ＋ increased significantly （ P ＆lt;0 .05） .Compared with the control group after treatment ,CD8 ＋ and the ratio of CD4 ＋ /CD8 ＋ in the treatment group after treatment were different significantly （ P ＆lt; 0 .05 ） . Nausea ,vomiting ,diarrhea and other adverse drug reactions were relatively mild in the treatment group ,but there were no significant difference （P＆gt; 0 .05） .We believe Huaier particles can significantly improve immune function in patients with greater clinical value and can be combined with gefitinib in patients with advanced lung cancer .